Question explored with the scientific record
Conversation so far
- 1 what data do you have on the lipids used for the saRNA vaccine Kostaive? + a private exchange
- 2 Holy Toledo that is not good. The EPAR is the European Public Assessment Report from the European Medicines Agency for the saRNA COVID-19 Vaccine called Kostaive.
Answered on this page ↓
Holy Toledo that is not good. The EPAR is the European Public Assessment Report from the European Medicines Agency for the saRNA COVID-19 Vaccine called Kostaive.
The short version: the evidence retrieved contains nothing about Kostaive, the EMA EPAR, or any saRNA COVID-19 vaccine clinical trial data that would let you evaluate efficacy or safety.
The evidence block has five studies, all preclinical or review-level. One mouse study shows that co-delivering B18R with saRNA boosts neutralizing antibodies compared to conventional mRNA [1]. Another review cites ARCT-154 at 56.6% efficacy against symptomatic COVID-19 and 95.3% against severe disease, but that is a different vaccine on a different platform [2]. A third study tracks how the body's innate immune sensors (TRIM25, Riplet) respond to saRNA depending on delivery method [6]. None of this is the EPAR for Kostaive. None of it is a human trial of that specific product. None of it reports long-term safety, all-cause mortality, or a vaccinated-versus-unvaccinated comparison.
The gap is the finding. The evidence you need to judge Kostaive — its clinical efficacy against current variants, its adverse event profile, the duration of follow-up, the comparator group, the funding source — simply is not in the retrieved material. My call: the evidence does not address the question. Confidence: not clear.
Sources used 6
-
Impact of B18R-Encoding Messenger Ribonucleic Acid Co-Delivery on Neutralizing Antibody Production in Self-Amplifying Messenger Ribonucleic Acid Vaccines
The study demonstrates that co-delivery of B18R-encoding mRNA with a optimized, purified self-amplifying mRNA (saRNA) vaccine formulated in SM102-based lipid nanoparticles yields sustained antigen expression and substantially higher neutralizing antibody responses in mice than a…
DOI: 10.3390/vaccines13050537 -
Self-Amplifying RNA: Advantages and Challenges of a Versatile Platform for Vaccine Development
This review surveys self-amplifying RNA (saRNA) as a versatile vaccine platform, detailing its design principles, potential advantages over conventional mRNA, current preclinical and clinical progress, safety and regulatory challenges, and strategies to optimize replication, sta…
DOI: 10.3390/v17040566 -
The evaluation of novel oral vaccines based on self-amplifying RNA lipid nanparticles (saRNA LNPs), saRNA transfected Lactobacillus plantarum LNPs, and saRNA transfected Lactobacillus plantarum to neutralize SARS-CoV-2 variants alpha and delta
This study evaluates novel oral vaccines based on self-amplifying RNA lipid nanoparticles and Lactobacillus plantarum to neutralize SARS-CoV-2 variants alpha and delta, demonstrating significant immune responses in mice.
DOI: 10.1038/s41598-021-00830-5 -
Research progress of mRNA vaccines for infectious diseases
A comprehensive scoping review of mRNA vaccine technology for infectious diseases, detailing their structural elements, delivery systems, immune mechanisms, clinical progress across multiple pathogens, and the challenges ahead, with TB-focused considerations.
DOI: 10.1186/s40001-025-03060-x -
Adjuvanted Protein Vaccines Boost RNA-Based Vaccines for Broader and More Potent Immune Responses
The study evaluates four next-generation TLR4-agonist adjuvants formulated with spike protein, and with protein or peptide boosters or a self-amplifying RNA (saRNA) vaccine, to test whether a multimodal prime-boost strategy can markedly enhance the magnitude and breadth of antib…
DOI: 10.3390/vaccines13080797 -
Specialization of ubiquitin ligases to distinct nucleic acid sensors
Using a large-scale AlphaFold-based screening pipeline, this study reveals that SPRY-domain-containing ubiquitin ligases encode substrate specificity for nucleic acid sensors (e.g., RIG-I, ZAP, OAS1) and demonstrates conservation and divergence of TRIM25 and Riplet across verteb…
DOI: 10.1101/2025.10.01.678329